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Novavax is a clinical stage biotechnology company with a technology platform to rapidly produce recombinant 
nanoparticle vaccines in response to emerging pathogens. Novavax utilizes a Sf9 insect cell/baculovirus (BV) 
expression system to produce recombinant protein nanoparticles based on correctly folded, protein-protein 
oligomers in a stable formulation. Novavax has utilized this expression system in developing a respiratory 
syncytial virus (RSV) F-protein nanoparticle vaccine candidate, currently in a global Phase 3 clinical trial to 
protect infants via maternal immunization and a Phase 2 trial in older adults. Using this platform, Novavax 
rapidly developed vaccine candidates in response to emerging pathogens such as Ebola and MERS, and 
currently has a program focused on a vaccine candidate for Zika. Novavax’ proprietary saponin-based adjuvant 
system (Matrix-MTM) is believed to enhance the immune response by eliciting broadly neutralizing antibodies 
and cellular immunity. In addition, Matrix-M has been well tolerated in over 1200 humans when used with 
vaccine antigens. The standardization of a platform manufacturing process and analytical tools, the utilization of 
a flexible manufacturing system, and the rapid response enabled by the insect cell/BV expression system all 
accelerate the timeline from discovery to clinical trial results. 
